Bladder cancer: atezolizumab safe, effective in real-world study

  • Sternberg CN & al.
  • Eur Urol
  • 22 Mar 2019

  • curated by Deepa Koli
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Real-world SAUL study shows atezolizumab is tolerable and effective in patients with urinary tract carcinoma, including those with renal impairment or autoimmune diseases.

Why this matters

  • Findings support atezolizumab benefit observed in IMvigor211 study.

Study design

  • Multicenter international open-label phase 3B safety study, SAUL.
  • 997 patients with locally advanced or metastatic urothelial or nonurothelial carcinoma of the urinary tract received atezolizumab.
  • Primary endpoint: safety.
  • Funding: F. Hoffmann-La Roche, Basel, Switzerland.

Key results

  • 35% of patients were ineligible as per IMvigor211 inclusion criteria. 
  • Median duration of follow-up was 12.7 months.
  • 45% of patients experienced grade ≥3 adverse events; most common were fatigue, asthenia, colitis, and hypertension.
  • Median OS was 8.7 (95% CI, 7.8-9.9) months, and PFS was 2.2 (95% CI, 2.1-2.4) months.
  • Median OS was 5.7 months in patients with renal impairment (n=46) and 8.2 months in those with autoimmune disease (n=35).
  • 6-month OS rate was 60% (95% CI, 57%-63%); median objective response rate (ORR) was 13% (95% CI, 11%-16%).
  • In IMvigor211-like patients, median OS was 10.0 (95% CI, 8.8-11.9) months, 6-month OS was 65% (95% CI, 61%-69%), and ORR was 14% (95% CI, 11%-17%).
  • Toxicity-related discontinuation rate was 8%.

Limitations

  • Lack of comparator group.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit